ClinicalTrials.gg
RecruitingNCT06814184virtual careUpdated Jul 2, 2026

Virtual Diabetes Care for Adults With Type 2 Diabetes on Medicaid and Insulin Therapy

An interventional study of app-based nurse-led virtual diabetes care in Type 2 Diabetes, sponsored by Rutgers, The State University of New Jersey. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-07-02.

Sponsored by Rutgers, The State University of New Jersey · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 7 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey — 5 open to participants now, 5 under way, 1 of them phase 3. Diabetes Mellitus, Type 2 · Rutgers, The State University of New Jersey.

Planned enrollment
4th of 12
60 · median 54
Started
2026
with 2 others
No phase
11 of 12
4 open now
Registered
9th of 12
by date

Among the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, this one is the 4th largest by planned enrollment, is one of 3 that started in 2026, is one of 11 with no phase, and was the 9th registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

5 of the 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Diabetes Mellitus, Type 2 by Rutgers, The State University of New Jersey, or all of them as a file.
02

Study summary

This 12-month pilot tests a nurse-led, app-based intervention to improve diabetes self-management for Medicaid patients. It includes MyChart messaging to give education, phone help on problem-solving with clinicians, and using a diabetes app to track data. The study aims to enhance self-management behaviors through health technology.

Read the detailed description

Guided by the Self- and Family Management Framework, which specifies facilitators and barriers to self- management behaviors, this project tests strategies for delivering virtual diabetes care to help Medicaid patients and clinicians use health information technology to support self-management behaviors. It is a 12-month pilot nurse-led, app-based behavioral intervention consisting of three evidence-based interventions: (1) education on A1C results and goal-setting via MyChart, the Epic electronic health record's patient portal; (2) a problem-solving action plan developed collaboratively by clinicians and patients; and (3) remote monitoring via mySugr, a top- rated diabetes app, to track blood glucose and identify the need for treatment adjustments.

03

Conditions studied

  • Type 2 Diabetes

Keywords

  • diabetes app
  • behavioral intervention
  • self-management
  • diabetes
04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • >7 for age 18-64, A1C>8 for age 65 or older within 12 months prior baseline
  • A1C>7 for age 18-64, A1c>8 for age 65 or older at baseline
  • Medicaid recipient or dual Medicaid and Medicare recipient
  • Age 18 or older
  • Type 2 diabetes
  • On insulin therapy
  • Owning and using Android or iOS smartphone for at least 6 months
  • English proficiency
  • Adequate vision to read text messages on their current smartphone
  • Smartphone use proficiency. Smartphone proficiency will be self-reported and determined by telephone as the ability to use a smartphone in ways other than emailing, texting, and making phone calls.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Patients with cognitive impairment who will be screened with the Six-Item Screener to Identify Cognitive Impairment Among Potential Research Subjects.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Experimental with intervention

    Intervention starts at enrollment

    Behavioral: app-based nurse-led virtual diabetes care

  • Other
    Delayed Intervention

    Intervention delivery 3 months after enrollment

    Behavioral: app-based nurse-led virtual diabetes care

Interventions

  • Behavioralapp-based nurse-led virtual diabetes care

    A nurse-led, app-based behavioral intervention consisting of (1) education via MyChart messaging, (2) problem solving with an action plan via phone, and (3) remote patient monitoring via mySugr app to identify the need to adjust treatment

06

What researchers measure

Primary outcomes

  1. Glycemic control: glycated hemoglobin AIC

    Electronic health record extracted lab test drawn at baseline, 3, 6, 9, and 12 months

    Time frame: baseline, 3, 6, 9, and 12 months

  2. Glycemic control - the rate of pre-prandial blood glucose readings in target range

    Home monitoring glucometer at baseline and diabetes app report containing blood glucose readings at home for 3, 6, 9, and 12 months. It is calculated from the number of BG that met the target divided by the total number of BG tested.

    Time frame: baseline, 3, 6, 9, and 12 months

  3. Glycemic control - the rate of peak postprandial blood glucose reading in target range

    Blood glucose reading obtained from patient's home monitoring glucometer at baseline and diabetes app report containing blood glucose readings at home for 3, 6, 9, and 12 months. It is calculated from the number of BG that met the target divided by the total number of BG tested.

    Time frame: baseline, 3, 6, 9, and 12 months

Secondary outcomes

  1. Diabetes Knowledge Test 2 (23 iems) for knowledge change

    This scale assesses the knowledge of individuals regarding diabetes management and self-care. 0 is minimal and 23 is maximal. Higher is better outcome reflecting high knowledge.

    Time frame: baseline, 3, 6, 9, and 12 months

  2. Diabetes Empowerment Scale Short 28 items for self-efficacy change

    The DES-28 has been validated and is considered a reliable tool for assessing the psychosocial aspects of diabetes management, making it useful for various educational and psychosocial interventions related to diabetes. 28 is minimal, 140 is max. Higher is better outcome, reflecting greater empowerment and self-efficacy in managing diabetes.

    Time frame: baseline, 3, 6, 9, and 12 months

  3. AHC Health-Related Social Needs Screening Tool (10 items) for Social Determinants of Health Change

    It help healthcare providers identifies the social needs of their patients, which can inform interventions and resource allocation. 0 is minimal, 10 is max. Higher score is greater number of identified health-related social needs, which may suggest worse outcomes in terms of social determinants of health.

    Time frame: baseline, 3, 6, 9, and 12 months

  4. Brief Cope Inventory (28 items) for effective and ineffective ways to cope with stressful life events.

    The Brief Coping Inventory is a 28-item measure that assesses 14 distinct coping strategies, with two items representing each strategy. It provides insight into how individuals manage challenges related to diabetes and general life stressors. Each item is rated on a 4-point scale ranging from 1 ("not at all") to 4 ("a lot"). Scores for each coping strategy range from 2 to 8, with higher scores indicating greater use of that specific coping style. The total score for the full inventory ranges from 28 to 112, with higher overall scores reflecting a greater reliance on coping strategies across domains.

    Time frame: baseline, 3, 6, 9, and 12 months

  5. Diabetes Distress Scale (17 items) for quality of life change

    Measures emotional distress related to managing diabetes, with scores for each item ranging from 1 ("not a problem") to 6 ("a very serious problem"). It is a valuable tool for identifying patients who may need additional support in managing the emotional burdens associated with diabetes. 17 is minimal, 102 is max. Higher scores indicate greater diabetes-related distress, which is generally considered worse for overall well-being and diabetes management. Scores are typically categorized as little/no distress, moderate distress, or high distress to guide interventions.

    Time frame: baseline, 3, 6, 9, and 12 months

  6. Summary of Diabetes Self-Care Activities Measure (11 items) for Self-management activity changes

    It is a reliable and valid tool for evaluating diabetes self-management behaviors and is useful in both research and clinical settings. 0 is minimal indicating no self-care activities performed, 11 is max indicating all self-care activities performed. Higher score indicate Measure consists of 11 items that assess various aspects of diabetes self-management.

    Time frame: baseline, 3, 6, 9, and 12 months

  7. Blood Glucose (BG) testing frequency change

    The number of blood glucose readings obtained from patient's home monitoring glucometer at baseline and the number of blood glucose readings listed in the diabetes app report at home for 3, 6, 9, and 12 months.

    Time frame: baseline, 3, 6, 9, and 12 months

  8. Diabetes Numeracy Test short (15 items) for knowledge change

    This test assesses diabetes-related numeracy skills that are essential for effective self-management of diabetes, such as interpreting blood glucose readings and calculating carbohydrate intake. 0-15, 0 is minimal with no correct answer, 15 is max. Higher is better outcome reflecting higher numeracy.

    Time frame: baseline, 3, 6, 9, and 12 months

07

Study locations

2 of 2 sites recruiting
  • Rutgers Health Family Medicine at Monument Square
    New Brunswick, New Jersey 08901, United States
    Recruiting
  • University Medical Group General Internal Medicine
    New Brunswick, New Jersey 08901, United States
    Recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — IPD will not be shared. Each participant will be given a unique study identification number that will be used on all study forms and data files. Each participant's identifying data will be separated from the study data. All data will be de-identified with a participant code number. The code linking a participant to their code number will be maintained in a separate file on a secure server at Rutgers (e.g., Microsoft Teams, Box).

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Dec 2028, 32 months after the start.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's planned 32 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 1, 2025
First posted
Feb 7, 2025
StartActual
Apr 1, 2026
Primary completionEst.
Dec 1, 2028
CompletionEst.
Dec 1, 2028
Last update
Jul 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06814184
Responsible party
Helen NC Chen PhD, FNP (PHD RN CRNP, Rutgers, The State University of New Jersey) — Principal investigator
First posted
Feb 7, 2025
Start date
Apr 1, 2026
Primary completion
Dec 1, 2028 (estimated)
Completion
Dec 1, 2028 (estimated)
Last update
Jul 2, 2026

Study contacts

Helen NC Chen, PhD
Contact
helen.nc.chen@rutgers.edu
(908) 466-3953
Toya Williams, MPH
Contact
toya.williams@rutgers.edu
‭(732) 235-7380‬
Helen NC Chen, PhD
principal investigator · Rutgers School of Nursing

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion